Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on March 17, 2015. The filing discloses the approval of executive compensation arrangements by the Company's compensation committee, specifically covering 2014 non-equity incentive payments, 2015 base salaries, and stock option grants for named executive officers.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details.
Material Changes and Compensation Details
The Board approved the following compensation for named executive officers:
- 2014 Non-Equity Incentive Payments: Paid in Canadian dollars and converted to U.S. dollars using an exchange rate of 0.9057.
- Simon N. Pimstone (CEO): $177,609
- Ian C. Mortimer (CFO/COO): $112,705
- Y. Paul Goldberg (VP, Clinical Development): $94,921
- Karen G. Corraini (General Counsel): $82,848
- Robin Sherrington (SVP, Business Development): $80,960
- 2015 Base Salaries: Paid in Canadian dollars, retroactive to January 1, 2015.
- Simon N. Pimstone: $419,656 CAD
- Ian C. Mortimer: $326,655 CAD
- Y. Paul Goldberg: $308,422 CAD
- Karen G. Corraini: $295,329 CAD
- Robin Sherrington: $296,261 CAD
- Stock Option Grants: Granted on March 17, 2015, with an exercise price of $17.76 (closing price on NASDAQ).
- Simon N. Pimstone: 95,000 shares
- Ian C. Mortimer: 55,000 shares
- Y. Paul Goldberg: 35,000 shares
- Karen G. Corraini: 35,000 shares
- Robin Sherrington: 35,000 shares
Vesting Schedule: 25% of options vest on January 1, 2016; the remaining 75% vest in equal monthly amounts over the subsequent three years.
Outlook, Risks, and Management Commentary
Performance goals for the 2015 non-equity incentive plan (up to 50% of base salary for the CEO and 35-40% for others) are tied to specific corporate objectives, including:
- Achievement of TV-45070 project goals in collaboration with Teva Pharmaceuticals.
- Execution of the collaboration with Genentech, Inc.
- Initiation of a Phase 2 proof-of-concept trial for XEN801.
- Progress in the Nav1.6 Dravet Syndrome program.
- Identification of the next ion channel program for discovery.
- Execution of the capital markets plan and budget management.
The filing does not explicitly list new risks or contingencies beyond the standard performance targets required for incentive compensation.
Investor Verification Checklist
- Verify the impact of the 2015 base salary increases on the Company's operating expenses.
- Confirm the status of the TV-45070 collaboration with Teva and the XEN801 Phase 2 trial initiation.
- Review the Company's cash position to ensure it can support the new salary commitments and potential incentive payouts.
- Monitor the vesting schedule of the 255,000 total options granted to assess future dilution.